Premium
A case of hepatosplenic γ – δ T‐cell lymphoma with a transient response to Fludarabine and Alemtuzumab
Author(s) -
Mittal S.,
Milner B. J.,
Johnston P. W.,
Culligan D. J.
Publication year - 2006
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2006.00646.x
Subject(s) - alemtuzumab , fludarabine , medicine , lymphoma , chemotherapy , regimen , oncology , surgery , cyclophosphamide , transplantation
Hepatosplenic γ – δ T‐cell lymphoma is a rare, usually fatal lymphoma and available literature on management is sparse. Allografting is probably the only curative option. We describe a further case with a dramatic, though transient response to Fludarabine and Alemtuzumab combination, following a failure of conventional chemotherapy. Given the dreadful prognosis with conventional chemotherapy, it is a regimen worth pursuing as a disease reduction strategy prior to allograft where appropriate.